{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T13:40:20Z","timestamp":1794663620118,"version":"4.9.1"},"reference-count":67,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,2,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Patients with GATA2 deficiencyharbor de novo or inherited germline mutations in the GATA2 transcription factor gene, predisposing them to myeloid malignancies. There is considerable variation in disease progression, even among family members with the same mutation in GATA2. We investigated somatic mutations in 106 patients with GATA2 deficiency to identify acquired mutations that are associated with myeloid malignancies. Myelodysplastic syndrome (MDS) was the most common diagnosis (\u223c44%), followed by GATA2 bone marrow immunodeficiency disorder (G2BMID; \u223c37%). Thirteen percent of the cohort had GATA2 mutations but displayed no disease manifestations. There were no correlations between age or sex with disease progression or survival. Cytogenetic analyses showed a high incidence of abnormalities (\u223c43%), notably trisomy 8 (\u223c23%) and monosomy 7 (\u223c12%), but the changes did not correlate with lower survival. Somatic mutations in ASXL1 and STAG2 were detected in \u223c25% of patients, although the mutations were rarely concomitant. Mutations in DNMT3A were found in \u223c10% of patients. These somatic mutations were found similarly in G2BMID and MDS, suggesting clonal hematopoiesis in early stages of disease, before the onset of MDS. ASXL1 mutations conferred a lower survival probability and were more prevalent in female patients. STAG2 mutations also conferred a lower survival probability, but did not show a statistically significant sex bias. There was a conspicuous absence of many commonly mutated genes associated with myeloid malignancies, including TET2, IDH1\/2, and the splicing factor genes. Notably, somatic mutations in chromatin-related genes and cohesin genes characterized disease progression in GATA2 deficiency.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021005065","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T16:19:16Z","timestamp":1631809156000},"page":"793-807","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":57,"title":["<i>ASXL1<\/i>\n                    and\n                    <i>STAG2<\/i>\n                    are common mutations in GATA2 deficiency patients with bone marrow disease and myelodysplastic syndrome"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2079-0922","authenticated-orcid":false,"given":"Robert R.","family":"West","sequence":"first","affiliation":[{"name":"Immune Deficiency-Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine R.","family":"Calvo","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, NIH Clinical Center, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa J.","family":"Embree","sequence":"additional","affiliation":[{"name":"Immune Deficiency-Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, NIH Clinical Center, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Tuschong","sequence":"additional","affiliation":[{"name":"Immune Deficiency-Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5614-7333","authenticated-orcid":false,"suffix":"Jr","given":"Thomas R.","family":"Bauer","sequence":"additional","affiliation":[{"name":"Immune Deficiency-Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3568-6148","authenticated-orcid":false,"given":"Desiree","family":"Tillo","sequence":"additional","affiliation":[{"name":"Genomics Core, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Lack","sequence":"additional","affiliation":[{"name":"Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0655-3576","authenticated-orcid":false,"given":"Stephenie","family":"Droll","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, NIH Clinical Center, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6841-2122","authenticated-orcid":false,"given":"Amy P.","family":"Hsu","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Holland","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis D.","family":"Hickstein","sequence":"additional","affiliation":[{"name":"Immune Deficiency-Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,1,31]]},"reference":[{"issue":"10","key":"2022013116231463300_B1","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1182\/blood-2011-05-356352","article-title":"Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome","volume":"118","author":"Hsu","year":"2011","journal-title":"Blood."},{"issue":"8","key":"2022013116231463300_B2","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1182\/blood-2009-03-208629","article-title":"Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia","volume":"115","author":"Vinh","year":"2010","journal-title":"Blood."},{"issue":"2","key":"2022013116231463300_B3","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1084\/jem.20101459","article-title":"The human syndrome of dendritic cell, monocyte, B and NK lymphoid deficiency","volume":"208","author":"Bigley","year":"2011","journal-title":"J Exp Med."},{"issue":"10","key":"2022013116231463300_B4","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/ng.923","article-title":"Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome)","volume":"43","author":"Ostergaard","year":"2011","journal-title":"Nat Genet."},{"issue":"10","key":"2022013116231463300_B5","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/ng.913","article-title":"Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia","volume":"43","author":"Hahn","year":"2011","journal-title":"Nat Genet."},{"key":"2022013116231463300_B6","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.leukres.2018.11.013","article-title":"MDS-associated mutations in germline GATA2 mutated patients with hematologic manifestations","volume":"76","author":"McReynolds","year":"2019","journal-title":"Leuk Res."},{"issue":"1","key":"2022013116231463300_B7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1053\/j.seminhematol.2018.05.016","article-title":"Acquired and germline predisposition to bone marrow failure: Diagnostic features and clinical implications","volume":"56","author":"Kallen","year":"2019","journal-title":"Semin Hematol."},{"issue":"6","key":"2022013116231463300_B8","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1182\/blood-2013-07-515528","article-title":"GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity","volume":"123","author":"Spinner","year":"2014","journal-title":"Blood."},{"issue":"2","key":"2022013116231463300_B9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1053\/j.seminhematol.2017.05.002","article-title":"GATA2 deficiency and related myeloid neoplasms","volume":"54","author":"Wlodarski","year":"2017","journal-title":"Semin Hematol."},{"issue":"1","key":"2022013116231463300_B10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/blood.2019000937","article-title":"Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA)","volume":"136","author":"Brown","year":"2020","journal-title":"Blood."},{"key":"2022013116231463300_B11","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1053\/shem.2002.36921","article-title":"Molecular genetics of human leukemias: new insights into therapy","volume":"39","author":"Gilliland","year":"2002","journal-title":"Semin Hematol."},{"issue":"6","key":"2022013116231463300_B12","doi-asserted-by":"crossref","first-page":"890","DOI":"10.3324\/haematol.2011.054361","article-title":"Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival","volume":"97","author":"B\u00f6d\u00f6r","year":"2012","journal-title":"Haematologica."},{"issue":"2","key":"2022013116231463300_B13","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3324\/haematol.2013.090217","article-title":"Acquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation","volume":"99","author":"West","year":"2014","journal-title":"Haematologica."},{"issue":"D1","key":"2022013116231463300_B14","doi-asserted-by":"crossref","first-page":"D886","DOI":"10.1093\/nar\/gky1016","article-title":"CADD: predicting the deleteriousness of variants throughout the human genome","volume":"47","author":"Rentzsch","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"6","key":"2022013116231463300_B15","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.bbmt.2018.01.030","article-title":"Allogeneic hematopoietic stem cell transplantation for GATA2 deficiency using a busulfan-based regimen","volume":"24","author":"Parta","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"key":"2022013116231463300_B16","article-title":"Donor source and post-transplantation cyclophosphamide influence outcome in allogeneic stem cell transplantation for GATA2 deficiency","author":"Nichols-Vinueza","year":"2021","journal-title":"Br J Haematol"},{"key":"2022013116231463300_B17","first-page":"97","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.","author":"Swerdlow","year":"2017","edition":"4th ed."},{"issue":"18","key":"2022013116231463300_B18","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1182\/bloodadvances.2020002953","article-title":"Human GATA2 mutations and hematologic disease: how many paths to pathogenesis?","volume":"4","author":"Bresnick","year":"2020","journal-title":"Blood Adv."},{"issue":"7714","key":"2022013116231463300_B19","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41586-018-0317-6","article-title":"Prediction of acute myeloid leukaemia risk in healthy individuals","volume":"559","author":"Abelson","year":"2018","journal-title":"Nature."},{"issue":"2","key":"2022013116231463300_B20","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/leu.2012.174","article-title":"GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis","volume":"27","author":"Fasan","year":"2013","journal-title":"Leukemia."},{"issue":"2","key":"2022013116231463300_B21","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia."},{"issue":"2","key":"2022013116231463300_B22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/MOH.0000000000000567","article-title":"Driver mutations in acute myeloid leukemia","volume":"27","author":"Kishtagari","year":"2020","journal-title":"Curr Opin Hematol."},{"issue":"23","key":"2022013116231463300_B23","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med."},{"issue":"D1","key":"2022013116231463300_B24","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: the catalogue of somatic mutations in cancer","volume":"47","author":"Tate","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"2022013116231463300_B25","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/bloodadvances.2020002854","article-title":"Somatic GATA2 mutations define a subgroup of myeloid malignancy patients at high risk for invasive fungal disease","volume":"5","author":"Vedula","year":"2021","journal-title":"Blood Adv."},{"issue":"2077","key":"2022013116231463300_B26","doi-asserted-by":"crossref","first-page":"579221","DOI":"10.3389\/fonc.2020.579221","article-title":"Comparison and implications of mutational profiles of myelodysplastic syndromes, myeloproliferative neoplasms, and myelodysplastic\/myeloproliferative neoplasms: a meta-analysis","volume":"10","author":"Wan","year":"2020","journal-title":"Front Oncol."},{"issue":"20","key":"2022013116231463300_B27","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1182\/bloodadvances.2018016840","article-title":"Genetic heterogeneity of cytogenetically normal AML with mutations of CEBPA.","volume":"2","author":"Konstandin","year":"2018","journal-title":"Blood Adv."},{"issue":"24","key":"2022013116231463300_B28","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1182\/blood-2016-03-705053","article-title":"Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors","volume":"127","author":"Lavall\u00e9e","year":"2016","journal-title":"Blood."},{"issue":"1","key":"2022013116231463300_B29","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/leu.2016.162","article-title":"Exome sequencing identifies highly recurrent somatic GATA2 and CEBPA mutations in acute erythroid leukemia","volume":"31","author":"Ping","year":"2017","journal-title":"Leukemia."},{"issue":"11","key":"2022013116231463300_B30","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1038\/leu.2016.185","article-title":"Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group","volume":"30","author":"Theis","year":"2016","journal-title":"Leukemia."},{"issue":"9","key":"2022013116231463300_B31","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41408-018-0123-2","article-title":"GATA2 zinc finger 1 mutations are associated with distinct clinico-biological features and outcomes different from GATA2 zinc finger 2 mutations in adult acute myeloid leukemia","volume":"8","author":"Tien","year":"2018","journal-title":"Blood Cancer J."},{"issue":"11","key":"2022013116231463300_B32","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1182\/blood-2015-09-669937","article-title":"Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents","volume":"127","author":"Wlodarski","year":"2016","journal-title":"Blood."},{"issue":"8","key":"2022013116231463300_B33","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.3324\/haematol.2017.181909","article-title":"Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients","volume":"103","author":"Donadieu","year":"2018","journal-title":"Haematologica."},{"issue":"8","key":"2022013116231463300_B34","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.3324\/haematol.2011.041152","article-title":"Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implications","volume":"96","author":"Calvo","year":"2011","journal-title":"Haematologica."},{"issue":"1","key":"2022013116231463300_B35","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1182\/blood-2014-06-580340","article-title":"GATA2 deficiency-associated bone marrow disorder differs from idiopathic aplastic anemia","volume":"125","author":"Ganapathi","year":"2015","journal-title":"Blood."},{"issue":"8","key":"2022013116231463300_B36","first-page":"467","article-title":"GATA2 null mutation associated with incomplete penetrance in a family with Emberger syndrome","volume":"22","author":"Brambila-Tapia","year":"2017","journal-title":"Hematology."},{"issue":"11","key":"2022013116231463300_B37","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1038\/s41375-018-0134-9","article-title":"GATA2 monoallelic expression underlies reduced penetrance in inherited GATA2-mutated MDS\/AML","volume":"32","author":"Al Seraihi","year":"2018","journal-title":"Leukemia."},{"issue":"13","key":"2022013116231463300_B38","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1080\/10428194.2019.1633630","article-title":"Phenotypic heterogeneity associated with germline GATA2 haploinsufficiency: a comprehensive kindred study","volume":"60","author":"Haddox","year":"2019","journal-title":"Leuk Lymphoma."},{"issue":"2","key":"2022013116231463300_B39","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/bjh.13317","article-title":"Haematopoietic and immune defects associated with GATA2 mutation","volume":"169","author":"Collin","year":"2015","journal-title":"Br J Haematol."},{"issue":"7","key":"2022013116231463300_B40","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1182\/bloodadvances.2016002311","article-title":"Somatic mutations in children with GATA2-associated myelodysplastic syndrome who lack other features of GATA2 deficiency","volume":"1","author":"Fisher","year":"2017","journal-title":"Blood Adv."},{"issue":"2","key":"2022013116231463300_B41","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s12185-017-2285-2","article-title":"Heterogeneity of GATA2-related myeloid neoplasms","volume":"106","author":"Hirabayashi","year":"2017","journal-title":"Int J Hematol."},{"issue":"6","key":"2022013116231463300_B42","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3324\/haematol.2015.137711","article-title":"Loss of B cells and their precursors is the most constant feature of GATA-2 deficiency in childhood myelodysplastic syndrome","volume":"101","author":"Nov\u00e1kov\u00e1","year":"2016","journal-title":"Haematologica."},{"issue":"3","key":"2022013116231463300_B43","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/leu.2016.342","article-title":"Mutational landscape in children with myelodysplastic syndromes is distinct from adults: specific somatic drivers and novel germline variants","volume":"31","author":"Pastor","year":"2017","journal-title":"Leukemia."},{"issue":"11","key":"2022013116231463300_B44","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.3390\/cells9112512","article-title":"The genomics of myelodysplastic syndromes: origins of disease evolution, biological pathways, and prognostic implications","volume":"9","author":"Awada","year":"2020","journal-title":"Cells."},{"issue":"8","key":"2022013116231463300_B45","doi-asserted-by":"crossref","first-page":"e26419","DOI":"10.1002\/pbc.26419","article-title":"A case of GATA2-related myelodysplastic syndrome with unbalanced translocation der(1;7)(q10;p10)","volume":"64","author":"Kurata","year":"2017","journal-title":"Pediatr Blood Cancer."},{"issue":"7","key":"2022013116231463300_B46","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/pbc.20478","article-title":"Shwachman-Diamond syndrome","volume":"45","author":"Dror","year":"2005","journal-title":"Pediatr Blood Cancer."},{"issue":"9","key":"2022013116231463300_B47","first-page":"496","article-title":"der(1;7)(q10;p10)","volume":"20","author":"Bruyre","year":"2016","journal-title":"Atlas Genet Cytogenet Oncol Haematol."},{"issue":"1","key":"2022013116231463300_B48","doi-asserted-by":"crossref","first-page":"5386","DOI":"10.1038\/s41467-019-13001-y","article-title":"Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes","volume":"10","author":"Nagata","year":"2019","journal-title":"Nat Commun."},{"issue":"12","key":"2022013116231463300_B49","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1038\/s41375-019-0617-3","article-title":"The functional mechanisms of mutations in myelodysplastic syndrome","volume":"33","author":"Nagata","year":"2019","journal-title":"Leukemia."},{"issue":"10","key":"2022013116231463300_B50","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1182\/blood-2018-10-844621","article-title":"Genetics of MDS","volume":"133","author":"Ogawa","year":"2019","journal-title":"Blood."},{"issue":"1","key":"2022013116231463300_B51","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1182\/hematology.2020000130","article-title":"Genomics of myelodysplastic syndrome\/myeloproliferative neoplasm overlap syndromes","volume":"2020","author":"Patnaik","year":"2020","journal-title":"Hematology (Am Soc Hematol Educ Program)."},{"issue":"3","key":"2022013116231463300_B52","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3390\/jcm9030802","article-title":"Landscape of Tumor suppressor mutations in acute myeloid leukemia","volume":"9","author":"Panuzzo","year":"2020","journal-title":"J Clin Med."},{"issue":"10","key":"2022013116231463300_B53","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/ng.2731","article-title":"Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms","volume":"45","author":"Kon","year":"2013","journal-title":"Nat Genet."},{"issue":"11","key":"2022013116231463300_B54","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1182\/blood-2014-04-567057","article-title":"Genetic alterations of the cohesin complex genes in myeloid malignancies","volume":"124","author":"Thota","year":"2014","journal-title":"Blood."},{"issue":"13","key":"2022013116231463300_B55","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1007\/s00018-019-03084-7","article-title":"The role of ASXL1 in hematopoiesis and myeloid malignancies","volume":"76","author":"Asada","year":"2019","journal-title":"Cell Mol Life Sci."},{"issue":"10","key":"2022013116231463300_B56","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1080\/10428194.2018.1433298","article-title":"ASXL1 mutations in AML are associated with specific clinical and cytogenetic characteristics","volume":"59","author":"Kakosaiou","year":"2018","journal-title":"Leuk Lymphoma."},{"issue":"3","key":"2022013116231463300_B57","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.neo.2021.01.003","article-title":"A cohesive look at leukemogenesis: The cohesin complex and other driving mutations in AML","volume":"23","author":"Heimbruch","year":"2021","journal-title":"Neoplasia."},{"issue":"1","key":"2022013116231463300_B58","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/leu.2016.256","article-title":"Mutational profiling of a MonoMAC syndrome family with GATA2 deficiency","volume":"31","author":"Ding","year":"2017","journal-title":"Leukemia."},{"issue":"13","key":"2022013116231463300_B59","article-title":"Somatic genetic and epigenetic architecture of myelodysplastic syndromes arising from GATA2 deficiency [abstract]","volume":"126","author":"Loyola","year":"2015","journal-title":"Blood."},{"issue":"2","key":"2022013116231463300_B60","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/ng.3742","article-title":"Dynamics of clonal evolution in myelodysplastic syndromes","volume":"49","author":"Makishima","year":"2017","journal-title":"Nat Genet."},{"issue":"2","key":"2022013116231463300_B61","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ccell.2019.06.007","article-title":"Mechanisms of progression of myeloid preleukemia to transformed myeloid leukemia in children with Down syndrome","volume":"36","author":"Labuhn","year":"2019","journal-title":"Cancer Cell."},{"issue":"11","key":"2022013116231463300_B62","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/ng.2759","article-title":"The landscape of somatic mutations in Down syndrome-related myeloid disorders","volume":"45","author":"Yoshida","year":"2013","journal-title":"Nat Genet."},{"issue":"8","key":"2022013116231463300_B63","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1080\/10428194.2018.1551535","article-title":"Myeloid malignancies with somatic GATA2 mutations can be associated with an immunodeficiency phenotype","volume":"60","author":"Alfayez","year":"2019","journal-title":"Leuk Lymphoma."},{"issue":"4","key":"2022013116231463300_B64","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1080\/10428194.2018.1516039","article-title":"Monozygotic twins with shared de novo GATA2 mutation but dissimilar phenotypes due to differential promoter methylation","volume":"60","author":"Kim","year":"2019","journal-title":"Leuk Lymphoma."},{"key":"2022013116231463300_B65","first-page":"100176","article-title":"Rapid progression to AML in a patient with germline GATA2 mutation and acquired NRAS Q61K mutation","volume":"12","author":"McReynolds","year":"2019","journal-title":"Leuk Res Rep."},{"issue":"10","key":"2022013116231463300_B66","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.3324\/haematol.2015.127092","article-title":"GATA2 and secondary mutations in familial myelodysplastic syndromes and pediatric myeloid malignancies","volume":"100","author":"Wang","year":"2015","journal-title":"Haematologica."},{"issue":"3","key":"2022013116231463300_B67","doi-asserted-by":"crossref","first-page":"e28865","DOI":"10.1002\/pbc.28865","article-title":"Venetoclax\/decitabine for a pediatric patient with chronic myelomonocytic leukemia","volume":"68","author":"Molina","year":"2021","journal-title":"Pediatr Blood Cancer."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/3\/793\/1866144\/advancesadv2021005065.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/3\/793\/1866144\/advancesadv2021005065.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T11:24:10Z","timestamp":1643628250000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/3\/793\/476936\/ASXL1-and-STAG2-are-common-mutations-in-GATA2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,31]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,2,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021005065","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,31]]}}}